Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
SPHERA FUNDS MANAGEMENT LTD. (CIK 1496201) reported $766.5M across 97 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: TEVA ($50.8M, 6.63%), BIIB ($42.5M, 5.54%), MLYS ($39.7M, 5.17%), TSEM ($28.2M, 3.68%), CYTK ($27.3M, 3.56%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $50.8M | 6.63% | 1.5M | Added |
| 2 | BIIB | BIOGEN INC | $42.5M | 5.54% | 196,626 | Added |
| 3 | MLYS | MINERALYS THERAPEUTICS INC | $39.7M | 5.17% | 1.5M | Added |
| 4 | TSEM | TOWER SEMICONDUCTOR LTD | $28.2M | 3.68% | 108,265 | Trimmed |
| 5 | CYTK | CYTOKINETICS INC | $27.3M | 3.56% | 319,987 | Added |
| 6 | XBI | SPDR SERIES TRUST | $23.7M | 3.10% | 150,000 | Trimmed |
| 7 | SNDX | SYNDAX PHARMACEUTICALS INC | $22.2M | 2.89% | 1.0M | Added |
| 8 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $19.6M | 2.56% | 588,494 | Trimmed |
| 9 | BMRN | BIOMARIN PHARMACEUTICAL INC | $18.8M | 2.45% | 328,550 | Added |
| 10 | BBIO | BRIDGEBIO PHARMA INC | $18.3M | 2.38% | 245,346 | Added |
| 11 | COGT | COGENT BIOSCIENCES INC | $17.8M | 2.32% | 459,340 | Added |
| 12 | NVMI | NOVA LTD | $13.7M | 1.78% | 25,169 | Trimmed |
| 13 | INSM | INSMED INC | $12.7M | 1.65% | 118,800 | New |
| 14 | MAZE | MAZE THERAPEUTICS INC | $12.5M | 1.63% | 417,564 | Added |
| 15 | AZN | ASTRAZENECA PLC | $11.9M | 1.55% | 62,530 | Hold |
| 16 | SNY | SANOFI SA | $11.5M | 1.50% | 269,515 | Hold |
| 17 | HELP | CYBIN INC | $10.7M | 1.40% | 1.6M | Added |
| 18 | LLY | ELI LILLY & CO | $9.6M | 1.26% | 8,040 | Trimmed |
| 19 | MDGL | MADRIGAL PHARMACEUTICALS INC | $9.4M | 1.22% | 17,419 | Added |
| 20 | ORIC | ORIC PHARMACEUTICALS INC | $9.2M | 1.21% | 852,983 | Added |
| 21 | TRVI | TREVI THERAPEUTICS INC | $9.3M | 1.21% | 499,029 | Trimmed |
| 22 | ACAD | ACADIA PHARMACEUTICALS INC | $9.0M | 1.18% | 356,534 | Added |
| 23 | CLDX | CELLDEX THERAPEUTICS INC NEW | $9.0M | 1.17% | 240,868 | Trimmed |
| 24 | RYTM | RHYTHM PHARMACEUTICALS INC | $8.9M | 1.16% | 80,400 | New |
| 25 | AMAT | APPLIED MATLS INC | $8.0M | 1.04% | 11,040 | New |
Source: SEC Form 13F filings · as of 2026-06-30